ICTHIOVAC® VR/PD contains 4 different antigens (P. damselae subs. piscicida, L. anguillarum serotype O1, L. anguillarum serotype O2a, L. anguillarum serotype O2b) and AQUAMUN, HIPRA’s adjuvant for aquaculture.
Conferring strong protection against Vibriosis and Pasteurellosis, ICTHIOVAC® VR/PD offers the perfect combination of long-lasting immunization, together with a reduced inflammatory reaction and less internal damage.
The negative impact of these two classic pathologies is becoming an increasing concern amongst Mediterranean producers, mainly due to the high prevalence resulting from the intensification of farming and the existence of natural reservoirs in the wild.
Participants were welcomed by Marta Perelló (Aqua Business Unit Coordinator at HIPRA), who apart from presenting HIPRA as a company, highlighted its distinctive values: quality, innovation and commitment, with Animal Health prevention as its main focus.
Continuing with the talks, Agnès Callol (Researcher and Project Manager at HIPRA’s Biological R&D Department) briefly presented all the different trials which were carried out during ICTHIOVAC® VR/PD development, mainly focusing on the safety and efficacy aspects of the vaccine.
To conclude the technical sessions, Erik Díaz (Product Manager at HIPRA) spoke about the current situation of Mediterranean aquaculture in terms of vaccination; from a practical point of view as well as the different important aspects which need to be taken into account when planning a vaccination.
Fish and vaccine performance, together with vaccination monitoring, were also topics discussed. Participants enjoyed a guided visit to the R&D and production facilities.
By organizing such an event, HIPRA reaffirms its commitment to prevention in Animal Health and particularly the Aquaculture sector.
